Yes, this is Barrett's esophagus
The biopsy findings of squamocolumnar mucosa with intestinal metaplasia confirm the diagnosis of Barrett's esophagus, regardless of the absence of dysplasia. The presence of intestinal metaplasia in columnar-lined esophagus is the defining histologic criterion for Barrett's esophagus according to current guidelines 1, 2, 3.
Diagnostic Confirmation
The key pathologic finding here is intestinal metaplasia in the squamocolumnar mucosa. This meets the diagnostic criteria for Barrett's esophagus, as established by major gastroenterology societies 1, 2, 3. While some international guidelines have debated whether intestinal metaplasia is required (with some accepting gastric-type metaplasia alone), the presence of intestinal metaplasia definitively establishes the diagnosis and is associated with higher cancer risk 4, 5.
The "mild inactive inflammation" noted in your biopsy is common and does not alter the diagnosis. The absence of dysplasia is actually favorable—it indicates you have non-dysplastic Barrett's esophagus, which carries the lowest risk of progression to cancer.
What This Means for Management
Since you have Barrett's esophagus without dysplasia, you should:
Enter an endoscopic surveillance program with intervals determined by the length of your Barrett's segment 1, 3:
- If Barrett's length is <3 cm: surveillance every 3-5 years
- If Barrett's length is ≥3 cm but <10 cm: surveillance every 2-3 years
- If Barrett's length is ≥10 cm: referral to a Barrett's expert center
Continue proton pump inhibitor therapy daily for symptom control and potentially to reduce progression risk 3
Follow a structured biopsy protocol at surveillance: 4-quadrant biopsies every 2 cm throughout the Barrett's segment, with separate biopsies of any visible abnormalities 1
Important Caveats
The diagnosis should be confirmed by an expert GI pathologist if not already done, given the significant interobserver variability in diagnosing Barrett's esophagus and dysplasia 2, 1. This is particularly important because the diagnosis has implications for long-term surveillance.
The mild inflammation noted should be addressed by optimizing acid suppression (typically twice-daily proton pump inhibitor) before any future surveillance biopsies, as inflammation can make dysplasia assessment difficult 2, 1.
Your annual risk of progression to high-grade dysplasia or cancer with non-dysplastic Barrett's is approximately 0.2-0.5% per year 1, which is why surveillance rather than immediate intervention is appropriate.